The session will review the profound opportunities of CAR-T cell therapy, adoptive cellular immunotherapies and checkpoint inhibitor therapy in the management of haematologic and metastatic solid tumours.
These Immunotherapies, by leveraging the patient's immune system, are transforming clinical care, resulting in prolonged survival and even cancer cures in a previously palliative setting. This event will review recent breakthroughs in the field, challenges and opportunities in the translation of scientific findings into the clinic and the promise of leveraging adaptive cellular therapies to tackle cancer clonal evolution for patient benefit.
2.15pm Welcome: Professor Julian Downward and Dr Samra Turajlic (The Francis Crick Institute)
2.20pm Speaker: Dr Iraj Ali (Achilles Therapeutics). "From bench to bedside: A CEO's view of cellular therapies and cancer."
2.50pm Speaker: Professor Adrian Hayday (The Francis Crick Institute). "Realising the therapeutic potentials of unique features of Gamma Delta T cells identified by basic research."
3.10pm Speaker: Professor Sergio Quezada (UCL Cancer Institute). "Targeting cancer immune checkpoints."
3.30pm Speaker: Professor MD Inge Marie Svane (University of Copenhagen). "TIL based T cell therapy, what is driving success?"
3.50pm Keynote Lecture: Dr Martin Pule (UCL Cancer Institute). "Achieving cures in haematologic malignancies with CAR-T cell therapies."
4.35pm Coffee, Tea, Networking
5.15pm Q&A and Panel Discussion. Panellists: Professor Charles Swanton (The Francis Crick Institute), Dr Iraj Ali (Achilles Therapeutics), Professor Adrian Hayday (The Francis Crick Institute), Professor Sergio Quezada (UCL Cancer Institute), Professor MD Inge Marie Svane (University of Copenhagen), Dr Martin Pule (UCL Cancer Institute)
Note: the titles of the talks are provisional and are just meant to reflect the topics; the actual titles will be decided by the speakers when the programme is finalised.
Registration, via Eventbrite, will open nearer the time.